Parkinson’s Disease Drugs Market | Growth, Trends, and Forecast (2019-2024)

Market Snapshot

Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

Key Players:

PURCHASE REPORT

$4250 SINGLE USER LICENSE

Only a single designated user can access the report.
Delivered in pdf format in 24 to 72 hours of purchase.
Comes with
3
months of post-purchase analyst support.

$4500 TEAM LICENSE

Up to 7 users can access the report.
Delivered in pdf format in 24 to 72 hours of purchase.
Comes with
3
months of post-purchase analyst support.

$8750 CORPORATE LICENSE

Any employee of your organization or its subsidiaries can access the report.
Delivered in pdf format in 24 to 72 hours of purchase.
Comes with
3
months of post-purchase analyst support.

Market Overview

Parkinson's disease is a chronic disorder that gradually leads to progressive deterioration of motor functions, due to the loss of dopamine-producing brain cells. Parkinson’s disease drugs market is expected to witness significant growth, due to the increasing cases of Parkinson’s disease, with the increase in aging population. Therefore, it may drastically result in increasing the market size, during the forecast period. Pharmaceutical firms are developing new and improved therapies for Parkinson's disease (PD) and in recently there have been some major product launches in Parkinson disease therapeutics and other assistive therapeutics. For example Adamas Pharmaceuticals’ amantadine extended-release capsules or Gocovri was launched in Jan 2018, which is the first drug indicated for dyskinesia developed due to long term usage of levodopa. Furthermore, most of the global firms have a robust drug pipeline for the treatment of Parkinson's disease, and as per the estimates, the forecast period may observe the launch of some blockbuster drugs.

Scope of the Report

Parkinson’s disease drugs market has been segmented on the basis of the mechanism of action and geography. Based on the mechanism of action, the market studied is segmented into dopamine agonists, anticholinergic, MAO-B inhibitors, amantadine, carbidopa-levodopa, COMT inhibitors, and other mechanisms of actions. Geographically, the market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

By Mechanism of Action
		Dopamine Agonists
		Anticholinergic
		MAO-B inhibitors
		Amantadine
		Carbidopa-levodopa
		COMT Inhibitors
		Other Mechanism of Actions

Geography

North America
	US
	Canada
	Mexico

Europe
	Germany
	UK
	France
	Italy
	Spain
	Rest of Europe

Asia Pacific
	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific

Middle East and Africa
	GCC
	South Africa
	Rest of Middle East and Africa

South America
	Brazil
	Argentina
	Rest of South America

Key Market Trends

Drugs Used In Conjugate Therapies Such as COMT (Catechol-O-Methyltransferase) Inhibitors are expected to Register Robust growth

Carbidopa-levodopa therapy is the most effective medication for alleviating the motor symptoms of PD, however, it has been observed that this medication is not so effective in the patients. Therefore, it is imperative that co-therapeutic agents such as COMT (catechol-O-methyltransferase) inhibitors are used along with carbidopa-levodopa therapy. The two most common COMT inhibitors, used in the treatment of Parkinson’s disease, are Comtan (entacapone) and Tasmar (tolcapone). Both of the medications can found to be available in the form of the tablet and these medications are being routinely prescribed in conjunction with carbidopa-levodopa therapy.

United States Represents the Largest Market for Parkinson's Disease Therapeutics

According to the National Institute of Health, approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by the year 2030. It is the second-most common neurodegenerative disorder in the United States. In addition, there are thousands of patients who go undetected. As the aging continues, the number of people living with Parkinson disease (PD) continues to grow and is expected to double by the year 2040. The sheer number of Parkinson’s disease patients combined with the availability of reimbursements and high awareness leads to the growth of the market. Furthermore, the high cost of Parkinson disease therapeutics in the United States also leads to huge market size in terms of revenue. The average cost of Parkinson’s medication is approximately USD 2,500 per year and Parkinson’s-related surgery can cost up to USD 100,000 per patient.

Competitive Landscape

The global Parkinson disease drugs market is becoming is highly competitive. The recent product launches and the high number of therapeutics in product pipelines of global pharmaceutical firms are contributing to the dynamic nature of the market. Several new product launches are expected during the forecast period which might lead to significant changes in market shares of pharmaceutical firms currently active in the market.

Major Players

* Complete list of players covered available in the table of contents below

Customize the Report

80% of our clients ask for some sort of customisation, be it specific countries / companies / segments.

What are you looking for?

1. INTRODUCTION
1. 1.1 Study Deliverables
2. 1.2 Study Assumptions
3. 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. 4.1 Market Overview
2. 4.2 Market Drivers
  1. 4.2.1 Rising Geriatric Population
  2. 4.2.2 Recent Drug Approvals
  3. 4.2.3 Increasing Awareness
3. 4.3 Market Restraints
  1. 4.3.1 Generic Competition to Key Therapies
  2. 4.3.2 High Cost of Treatment
4. 4.4 Porter's Five Force Analysis
  1. 4.4.1 Threat of New Entrants
  2. 4.4.2 Bargaining Power of Buyers/Consumers
  3. 4.4.3 Bargaining Power of Suppliers
  4. 4.4.4 Threat of Substitute Products
  5. 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. 5.1 By Mechanism of Action
  1. 5.1.1 Dopamine Agonists
  2. 5.1.2 Anticholinergic
  3. 5.1.3 MAO-B inhibitors
  4. 5.1.4 Amantadine
  5. 5.1.5 Carbidopa-levodopa
  6. 5.1.6 COMT Inhibitors
  7. 5.1.7 Other Mechanism of Actions
2. 5.2 Geography
  1. 5.2.1 North America
    1. 5.2.1.1 US
    2. 5.2.1.2 Canada
    3. 5.2.1.3 Mexico
  2. 5.2.2 Europe
    1. 5.2.2.1 Germany
    2. 5.2.2.2 UK
    3. 5.2.2.3 France
    4. 5.2.2.4 Italy
    5. 5.2.2.5 Spain
    6. 5.2.2.6 Rest of Europe
  3. 5.2.3 Asia Pacific
    1. 5.2.3.1 China
    2. 5.2.3.2 Japan
    3. 5.2.3.3 India
    4. 5.2.3.4 Australia
    5. 5.2.3.5 South Korea
    6. 5.2.3.6 Rest of Asia-Pacific
  4. 5.2.4 Middle East and Africa
    1. 5.2.4.1 GCC
    2. 5.2.4.2 South Africa
    3. 5.2.4.3 Rest of Middle East and Africa
  5. 5.2.5 South America
    1. 5.2.5.1 Brazil
    2. 5.2.5.2 Argentina
    3. 5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
1. 6.1 Company Profiles
  1. 6.1.1 Merck & Co. Inc.
  2. 6.1.2 Impax Laboratories Inc.
  3. 6.1.3 AbbVie Inc.
  4. 6.1.4 Mylan NV
  5. 6.1.5 Boehringer Ingelheim
  6. 6.1.6 GlaxoSmithKline PLC
  7. 6.1.7 M Somerset Pharmaceuticals Inc.
  8. 6.1.8 Teva Pharmaceuticals
  9. 6.1.9 Pfizer
  10. 6.1.10 Novartis AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments